These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Treatment Possibilities for Psychosis in Parkinson's Disease with An Emphasis on the Newly Approved Drug: Pimavanserin. Majlath Z; Obal I; Vecsei L CNS Neurol Disord Drug Targets; 2017; 16(3):234-243. PubMed ID: 27719624 [TBL] [Abstract][Full Text] [Related]
8. The safety, tolerability and efficacy of pimavanserin tartrate in the treatment of psychosis in Parkinson's disease. Hermanowicz S; Hermanowicz N Expert Rev Neurother; 2016 Jun; 16(6):625-33. PubMed ID: 26908168 [TBL] [Abstract][Full Text] [Related]
9. Falls and Fractures in Patients with Parkinson's Disease-Related Psychosis Treated with Pimavanserin vs Atypical Antipsychotics: A Cohort Study. Layton JB; Forns J; Turner ME; Dempsey C; Bartsch JL; Anthony MS; Danysh HE; Ritchey ME; Demos G Drugs Real World Outcomes; 2022 Mar; 9(1):9-22. PubMed ID: 34718963 [TBL] [Abstract][Full Text] [Related]
10. Pimavanserin and Parkinson's Disease Psychosis: A Narrative Review. Rissardo JP; Durante Í; Sharon I; Fornari Caprara AL Brain Sci; 2022 Sep; 12(10):. PubMed ID: 36291220 [TBL] [Abstract][Full Text] [Related]
11. Pimavanserin: A Novel Antipsychotic for Parkinson's Disease Psychosis. Bozymski KM; Lowe DK; Pasternak KM; Gatesman TL; Crouse EL Ann Pharmacother; 2017 Jun; 51(6):479-487. PubMed ID: 28375643 [TBL] [Abstract][Full Text] [Related]
12. Pimavanserin for the treatment of Parkinson's disease psychosis. Chendo I; Ferreira JJ Expert Opin Pharmacother; 2016 Oct; 17(15):2115-24. PubMed ID: 27609312 [TBL] [Abstract][Full Text] [Related]
13. Comparative Efficacy, Safety, and Acceptability of Pimavanserin and Other Atypical Antipsychotics for Parkinson's Disease Psychosis: Systematic Review and Network Meta-Analysis. Yunusa I; Rashid N; Seyedin R; Paratane D; Rajagopalan K J Geriatr Psychiatry Neurol; 2023 Sep; 36(5):417-432. PubMed ID: 36720473 [TBL] [Abstract][Full Text] [Related]
14. Successful treatment of clozapine-nonresponsive refractory hallucinations and delusions with pimavanserin, a serotonin 5HT-2A receptor inverse agonist. Nasrallah HA; Fedora R; Morton R Schizophr Res; 2019 Jun; 208():217-220. PubMed ID: 30837203 [TBL] [Abstract][Full Text] [Related]
15. A New Hope in Alzheimer's Disease Psychosis: Pimavanserin. Kurhan F; Akın M Curr Alzheimer Res; 2023; 20(6):403-408. PubMed ID: 37641988 [TBL] [Abstract][Full Text] [Related]
16. Hallucinations and delusions associated with Parkinson's disease psychosis: safety of current treatments and future directions. Isaacson SH; Citrome L Expert Opin Drug Saf; 2022 Jul; 21(7):873-879. PubMed ID: 35466847 [TBL] [Abstract][Full Text] [Related]
17. Clearing the Fog: A Review of Antipsychotics for Parkinson's-Related Hallucinations: A Focus on Pimavanserin, Quetiapine and Clozapine. Abdul-Rahman T; Herrera-Calderón RE; Aderinto N; Kundu M; Wireko AA; Adebusoye FT; Ekerin O; Lawal L; Mykolaivna NI; Alexiou A; Almashjary MN; Perveen A; Ashraf GM J Integr Neurosci; 2024 Apr; 23(4):80. PubMed ID: 38682215 [TBL] [Abstract][Full Text] [Related]
18. Mortality Among Parkinson's Disease Patients Treated With Pimavanserin or Atypical Antipsychotics: An Observational Study in Medicare Beneficiaries. Mosholder AD; Ma Y; Akhtar S; Podskalny GD; Feng Y; Lyu H; Liao J; Wei Y; Wernecke M; Leishear K; Nelson LM; MaCurdy TE; Kelman JA; Graham DJ Am J Psychiatry; 2022 Aug; 179(8):553-561. PubMed ID: 35702829 [TBL] [Abstract][Full Text] [Related]
19. Psychosis in Parkinson's Disease: Looking Beyond Dopaminergic Treatments. Rojas M; Chávez-Castillo M; Duran P; Ortega Á; Bautista-Sandoval MJ; Salazar J; Riaño-Garzón M; Chacín M; Medina-Ortiz O; Palmar J; Cudris-Torres L; Bermúdez V Curr Pharm Des; 2022; 28(33):2725-2741. PubMed ID: 36321314 [TBL] [Abstract][Full Text] [Related]